-+ 0.00%
-+ 0.00%
-+ 0.00%

Canaccord Genuity Maintains Buy on Helus Pharma, Raises Price Target to $58

Benzinga·11/17/2026 15:25:57
Listen to the news
Canaccord Genuity analyst Sumant Kulkarni maintains Helus Pharma (NASDAQ:HELP) with a Buy and raises the price target from $42 to $58.